Table 2.
Summary of PRS results from the first six batches of clinical samples in the GenoVA Study
| BrCa | CRCa | PrCa | AFib | CAD | T2D | |
|---|---|---|---|---|---|---|
| Total analyzed, n | 77 | 227 | 150a | 227 | 227 | 227 |
| Average risk, n (%) | 67 (87.0) | 214 (94.3) | 127 (84.7) | 203 (89.4) | 211 (92.9) | 210 (92.5) |
| High risk, n (%) | 10 (13.0) | 13 (5.7) | 23 (15.3) | 24 (10.6) | 16 (7.1) | 17 (7.5) |
Results from the first 227 GenoVA participants. High-risk PRS, defined here as PRSstd-adj associated with OR > 2 for disease in the original publication. All other results are considered as average risk.
aOne participant with male sex identifies as female.